OSRH Overview

OSR Holdings, Inc. is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, it is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its operating businesses include developing oral immunotherapies for the treatment of cancer, developing design-augmented (DA) biologics for age-related and other degenerative diseases and neurovascular intervention medical devices and systems distribution in Korea. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Vaximm is developing oral immunotherapies for the treatment of cancer and immunological disorders. RMC is a Korea-based neurovascular intervention medical device and systems distribution company. Darnatein is developing DA biologics for age-related and other degenerative diseases. Woori IO is a South Korea-based medical device company.

Wall Street analysts forecast OSRH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSRH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

OSR Holdings Inc revenue for the last quarter amounts to 484.06K USD, decreased -36.41

OSR Holdings Inc. EPS for the last quarter amounts to -0.09 USD, decreased -91.35

OSR Holdings Inc (OSRH) has 22 emplpoyees as of June 13 2026.

Today OSRH has the market capitalization of 14.72M USD.